MT5-MMP C-terminal mutations reduce C99 and β accumulation: A foundation for peptide-based Alzheimer's interventions
Pedro Belio MairaliD, Athina Kamitsou, Delphine StephaniD, Nicolas JullieniD, Diarra Thiane, Melissa Ramos, Laurence LouisiD, Florian Benoist, Baptiste Serrano, Marion DavidiD, Michel KhrestchatiskyiD, Pascaline Lécorché, Emmanuel NivetiD, Santiago RiveraiD
Abstract
Our prior work established a pivotal role for membrane-type 5-matrix metalloproteinase (MT5-MMP) in Alzheimers disease (AD) pathogenesis, particularly through its C-terminal transmembrane (TM) and intracellular (IC) domains, which influence the fate of major toxic metabolites of toxic amyloid precursor protein (APP) metabolites, particularly C99 and A{beta}. Hypothesizing that modifications in these domains could modulate C99 and A{beta} levels, we engineered MT5-MMP variants with deletions or substitutions in the TM/IC domains or specific IC amino acid clusters. When co-transfected into human cell lines accumulating C99, certain IC domain mutations promoted C99 degradation and reduced A{beta} levels, while other mutations had divergent effects. High content imaging further revealed that MT5-MMP IC domain modification altered C99 subcellular trafficking within the endomembrane system, impacting its processing. Proximity ligation assays confirmed the importance of the IC domain in MT5-MMP colocalization and potential interaction with C99. To translate these findings, we synthetized peptides mimicking the MT5-MMP IC domain, incorporating mutations that reduce C99 and/or A{beta} levels. One peptide effectively lowered C99 levels in an in vitro AD model. Overall, this study highlights the importance of specific amino acids in the C-terminal domains of MT5-MMP for regulating C99 and A{beta} metabolism. It also provides new insights for developing MT5-MMP-based therapeutic strategies against AD, exploiting the unique properties of specific mutations in MT5-MMP to prevent toxic accumulation of C99 and A{beta}. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=86 SRC="FIGDIR/small/655451v3_ufig1.gif" ALT="Figure 1"> View larger version (27K): org.highwire.dtl.DTLVardef@a6b04aorg.highwire.dtl.DTLVardef@1800721org.highwire.dtl.DTLVardef@542505org.highwire.dtl.DTLVardef@4a6d7b_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGRAPHICAL ABSTRACTC_FLOATNO C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- MT5-MMP controls APP metabolism and the fate of beta-CTF/C99 and Abeta through proteolytic-dependent and -independent mechanisms relevant for Alzheimer's disease
Laura García‐González, Jean‐Michel Paumier, … Santiago Rivera·The FASEB JournalPeer-reviewed·Jun 12, 2021
- Tight control of the APP-Mint1 interaction in regulating amyloid production
Shawna M. Henry, Sabrina A. Kistler, … Angela Ho·Brain ResearchPeer-reviewed·Jul 25, 2023
- C99 selectively accumulates in vulnerable neurons in Alzheimer’s disease
Maria V. Pulina, Maya Hopkins, … Victor Bustos·Alzheimer s & DementiaPeer-reviewed·Nov 3, 2019
- Post-translational modifications in the brain are critical contributors to Alzheimers disease neuropathology and cognitive decline
Julia B. Libby, Emily R. Mahoney, … Timothy J. Hohman·Alzheimer s & DementiaPeer-reviewed·Dec 1, 2025
- Structure of APP-C991-99 and Implications for Role of Extra-Membrane Domains in Function and Oligomerization
G. A. Pantelopulos, J. E. Straub, … Y. Sugita·bioRxiv·Feb 21, 2018
- Mutations in the juxtamembrane segment of the cholesterol-binding site of APP alter its processing and promotes production of shorter, less toxic Aβ peptides.
Linda Hanbouch, Béatrice Schaack, … Marie‐Claude Potier·bioRxiv·Nov 16, 2020